Scarica l'app Stockscreener
21.73
2.31%
0.49
Pre-mercato:
21.93
0.20
+0.92%
Pacira Biosciences Inc Borsa (PCRX) Ultime notizie
Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices - GlobeNewswire
Pacira BioSciences, Inc. $PCRX Holdings Raised by Impax Asset Management Group plc - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Pacira (PCRX) Issues Inducement Awards to New Employees Under 20 - GuruFocus
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
Pacira BioSciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Pacira hands new hires $21.02 stock options and RSUs - Stock Titan
Pacira BioSciences: Mispriced On Generic Risks That Are Years Away (NASDAQ:PCRX) - Seeking Alpha
2026-02-08 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Connect | NDAQ:PCRX | Press Release - Stockhouse
NJ Judges Tosses Pacira Investor Suit Over Patent Loss - Law360
2026-02-05 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Reach Out | NDAQ:PCRX | Press Release - Stockhouse
Avoiding Lag: Real-Time Signals in (PCRX) Movement - Stock Traders Daily
Pacira BioSciences (PCRX) Stock Price, News & Analysis - MarketBeat
Pacira BioSciences SVP Lauren Riker sells $83k in stock By Investing.com - Investing.com Nigeria
Pacira BioSciences SVP Lauren Riker sells $83k in stock - Investing.com
Pacira BioSciences (NASDAQ:PCRX) SVP Lauren Riker Sells 4,000 Shares - MarketBeat
Pacira BioSciences officer Williams sells $269k in shares By Investing.com - Investing.com Canada
Pacira BioSciences officer Williams sells $269k in shares - Investing.com
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates - TradingView
Pacira BioSciences, Inc. (PCRX) Stock Analysis: Unlocking a 40% Potential Upside in Non-Opioid Pain Management Solutions - DirectorsTalk Interviews
2026-02-01 | Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse
Great Lakes Advisors LLC Decreases Stake in Pacira BioSciences, Inc. $PCRX - MarketBeat
In A Strategic Move, Samit Hirawat Acquires Pacira BioSciences Stock Options Worth $9K: Enhancing Value - Benzinga
Gagnon Securities LLC Grows Stock Holdings in Pacira BioSciences, Inc. $PCRX - MarketBeat
Gap Down: What is Deluxe Corporations valuation compared to sectorQuarterly Trade Summary & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Pacira BioSciences appoints Samit Hirawat to board of directors By Investing.com - Investing.com Nigeria
Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
What are Pacira BioSciences Inc.’s technical support levels2025 Sector Review & Technical Buy Zone Confirmations - mfd.ru
Pacira appoints Samit Hirawat to board of directors - TipRanks
Bristol Myers Squibb (BMY) Exec Joins Pacira BioSciences Board - GuruFocus
Pacira BioSciences appoints Samit Hirawat to board of directors - Investing.com
Bristol Myers drug development leader joins Pacira board - Stock Titan
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors - Sahm
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Connect - ACCESS Newswire
Pacira BioSciences, Inc. (PCRX) Stock Analysis: Unveiling a 44.95% Potential Upside for Investors - DirectorsTalk Interviews
Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report? - Finviz
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
Discipline and Rules-Based Execution in PCRX Response - Stock Traders Daily
Volume Recap: Is Pacira BioSciences Inc a good ESG investment2025 Big Picture & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation - accessnewswire.com
Pacira partners with LG Chem to make EXPAREL® available in select APAC markets - BioSpectrum Asia
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Will Pacira BioSciences Inc. stock deliver shareholder valueDebt-to-Equity Ratio Analysis & Smarter Trades Backed by Machine Learning - bollywoodhelpline.com
DOMA Perpetual Capital to offer nominees for Pacira BioSciences board - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Reach Out - ACCESS Newswire
Revenues Working Against Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Share Price Following 28% Dive - simplywall.st
Benign Growth For Pacira BioSciences, Inc. (NASDAQ:PCRX) Underpins Stock's 28% Plummet - 富途牛牛
Pacira BioSciences Inc (PCRX) Stock Price Down 5.4% on Jan 16 - GuruFocus
Market Outlook: Is Great Elm Group Inc subject to activist investor interestPortfolio Performance Summary & Smart Swing Trading Alerts - baoquankhu1.vn
Pacira BioSciences (NASDAQ:PCRX) Hits New 52-Week LowTime to Sell? - MarketBeat
Do Options Traders Know Something About Pacira BioSciences Stock We Don't? - Nasdaq
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Connect - accessnewswire.com
Pacira BioSciences (NASDAQ:PCRX) Shares Down 6.9%What's Next? - MarketBeat
1.21%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):